Neuronetics Revenue Up 86% Powered by Strong NeuroStar Adoption

gas_fee_therapy · 2026-03-03T16:09:48+00:00

Neuronetics Inc. reported a remarkable fourth-quarter 2025, with revenue jumping 86% year-over-year to $41.8 million, driven by NeuroStar system demand. Full-year revenue reached $149.2 million, up 99%. Strong financials and positive cash flow boosted market confidence, leading to a notable stock increase.

gas_fee_therapy

2026-03-03 16:09:48

Abstract generation in progress

Neuronetics Inc. (STIM), a leading commercial-stage medical technology company, delivered impressive fourth-quarter 2025 results that signal robust growth momentum. The company’s reported Q4 revenue climbed to $41.8 million, up 86% year-over-year from $22.49 million in the prior year. Even when adjusting for pro forma basis, the preliminary Q4 2025 revenue grew 23% compared to the same period last year, reflecting genuine operational strength rather than accounting adjustments alone.

The revenue surge was primarily fueled by accelerating demand for NeuroStar Advanced Therapy System, the company’s flagship non-invasive treatment platform for Major Depressive Disorder and Obsessive-Compulsive Disorder. During the quarter, Neuronetics shipped 49 NeuroStar systems, generating $18.3 million in equipment revenue—a substantial jump from just $3.8 million a year earlier. This represents a particularly telling indicator of market adoption and clinical acceptance for the therapeutic solution.

NeuroStar Drives Multi-Channel Revenue Expansion

Beyond equipment sales, the company’s clinic operations demonstrated equally compelling momentum. Revenue from NeuroStar-equipped clinics surged to $23.5 million in Q4 2025, compared with only $4.4 million in the year-ago quarter. This revenue stream, derived from recurring treatment sessions and service contracts, underscores the sustainability of Neuronetics’ business model and the growing installed base generating recurring revenue.

Total full-year 2025 revenue reflected this positive trajectory, reaching $149.2 million—a 99% year-over-year increase from $74.9 million in 2024. On an adjusted pro forma basis, the full-year growth rate of 15% provides a more normalized view of underlying operational expansion.

Financial Health Strengthens Market Confidence

CEO Keith Sullivan emphasized the company’s operating leverage, noting: “We translated this strong revenue performance into positive operating cash flow during the quarter and maintained the strength of our balance sheet as we move into 2026.” Neuronetics ended 2025 with $34.1 million in total cash, cash equivalents, and restricted cash—a healthy reserve that supports continued investment in sales, marketing, and product development.

The market validated this performance immediately, with STIM stock rising nearly 30% in premarket trading on the earnings announcement day, closing the prior session at $1.46. The stock surged to $1.89 in early trading, reflecting investor enthusiasm for the company’s trajectory and the growing recognition of NeuroStar’s clinical and commercial potential in treating neuropsychiatric disorders.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.